Skip to main content
SpringerLink
Log in

Matrix Metalloproteinase-2 (MMP-2) is Associated with the Risk for a Relapse in Postmenopausal Patients with Node-Positive Breast Carcinoma Treated with Antiestrogen Adjuvant Therapy

  • Conference Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Node-positive breast carcinoma is an aggressive disease. Postmenopausal patients benefit from antiestrogen adjuvant therapy. Predictive markers could, however, be useful in selecting these patients for different modalities of adjuvant therapy. Recently, we showed that MMP-2 (72kD type IV collagenase/gelatinase A) is correlated with unfavorable prognosis in premenopausal breast carcinoma patients. Expression of the immunoreactive protein for MMP-2 was evaluated prospectively in this study in paraffin tissue sections from primary tumors of 100 postmenopausal, node-positive breast carcinoma patients treated with an adjuvant antiestrogen therapy. A specific MMP-2 monoclonal antibody in an avidin–biotin immunohistochemical staining was used. Sixty nine percent of the samples were MMP-2 positive. Eighty three percent of the MMP-2 negative patients lived for 5 years without a recurrence, while only 67% of the patients with an MMP-2 positive primary tumor were recurrence-free at that time (p<0.0; log rank analysis). MMP-2 positivity showed a significant correlation with shortened survival in patients with a small primary tumor (T1–2) and a low axillary tumor burden. One hundred percent of these patients with an MMP-2 negative breast carcinoma survived for 5 years, compared to 73% of the MMP-2 positive cases alive at that time (p=0.02). In conclusion, we show here that MMP-2 is a prognostic indicator in postmenopausal patients with node-positive breast carcinoma with a low tumor burden, and that it predicts a risk for failure in antiestrogen adjuvant therapy. It might have predictive value in selecting the most efficient adjuvant therapy in this set of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ries LG, Pollack ES, Young JL: Cancer patients survival: surveillance, epidemiology, and end results. J Natl Cancer Inst 70: 693-707, 1983

    Google Scholar 

  2. Shetty MR, Reiman HM Jr: Tumor size and axillary metastasis, a correlative occurence in 1244 cases of breast cancer between 1980 and 1995. Eur J Surg Oncol 23(2): 139-141, 1997

    Google Scholar 

  3. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980

    Google Scholar 

  4. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SS, Liotta LA: Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids which differ in metastatic potential. J Natl Cancer Inst 75: 99-103, 1985

    Google Scholar 

  5. Nakajima M, Welch DR, Belloni PN, Nicolson GL: Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 47: 4869-4876, 1987

    Google Scholar 

  6. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T: Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Path 186: 51-58, 1998

    Google Scholar 

  7. Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H: Expression of MMP (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 47: 461-469, 1997

    Google Scholar 

  8. Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG: Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 136: 585-592, 1990

    Google Scholar 

  9. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126-1131, 1993

    Google Scholar 

  10. Tryggvason K, Höyhtyä M, Pyke C: Type IV collagenases in invasive tumours. Breast Cancer Res Treat 24: 209-218, 1993

    Google Scholar 

  11. Daidone MG, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini WG, Garbisa S, Liotta LA, Grigioni WF: Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer 48: 529-532, 1991

    Google Scholar 

  12. Höyhtyä M, Fridman R, Komarck D, Porter-Jordan K, Stetler-Stevenson NG, Liotta LA, Liang CM: Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer 54: 500-505, 1994

    Google Scholar 

  13. Kurizaki T, Toi M, Tominaga T: Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncology Reports 5(3): 673-677, 1998

    Google Scholar 

  14. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 83: 1153-1162, 1998

    Google Scholar 

  15. Hermanek P, Sobin LH, (eds): UICC TNM Classification of malignant tumours 4th edn 2nd rev. Berlin: Springer-Verlag, 1992

    Google Scholar 

  16. Scarff RW, Torloni H: Histological typing of breast tumours. WHO: Geneva, 1986

    Google Scholar 

  17. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957

    Google Scholar 

  18. Hsu SM, Raine L, Fanger H: The use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase technique: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981

    Google Scholar 

  19. Marqulies IMK, Höyhtyä M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG: Urinary type IV collagenase elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomark Prev 467-474, 1992

  20. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 180: 283-289, 1996

    Google Scholar 

  21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958

    Google Scholar 

  22. Mantel N: Evaluation of survival data and two new rank order statistics arising in this consideration. Cancer Chemother Rep 50: 163-170, 1966

    Google Scholar 

  23. Norton L: A compertzian model of human breast cancer growth. Cancer Res 48: 7067-7071, 1988

    Google Scholar 

  24. D'Errico A, Garbisa S, Liotta LA, Castronovo V, Stetler-Stevenson WG, Griogioni WG: Augmentation of type IV collagenase, lamin in receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Med Pathol 4: 239-246, 1991

    Google Scholar 

  25. Campo E, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA, Merino MJ: Evaluation of basement membrane components and the 72KDa type IV collagenase in serous tumours of the ovary. Am J Pathol 6: 500-507, 1992

    Google Scholar 

  26. Visscher DW, Höyhtyä M, Ottosen SK, Liang C-M, Sarkar FH, Crissman JD: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in stroma of breast carcinomas correlates with tumour recurrence. Int J Cancer 59: 339-344, 1994

    Google Scholar 

  27. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M, Okada Y: Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 57: 2055-2060, 1997

    Google Scholar 

  28. Soini Y, Hurskainen T, Höyhtyä M, Oikarinen A, Autio-Harmainen H: 72KD and 92KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem 42: 945-951, 1994

    Google Scholar 

  29. Väisänen A, Kallioinen M, von Dickhoff K, Laatikainen L, Höyhtyä M, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) immunoreactive protein-a new prognostic marker in uveal melanoma? J Pathol 188: 56-62, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Radiotherapy, University of Oulu and Oulu University Hospital, Oulu, Finland

    A. Talvensaari-Mattila, G. Blanco-Sequeiros & T. Turpeenniemi-Hujanen

  2. Department of Pathology, University of Oulu and Oulu University Hospital, Oulu, Finland

    P. Pääkkö

Authors
  1. A. Talvensaari-Mattila
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Pääkkö
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Blanco-Sequeiros
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Turpeenniemi-Hujanen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talvensaari-Mattila, A., Pääkkö, P., Blanco-Sequeiros, G. et al. Matrix Metalloproteinase-2 (MMP-2) is Associated with the Risk for a Relapse in Postmenopausal Patients with Node-Positive Breast Carcinoma Treated with Antiestrogen Adjuvant Therapy. Breast Cancer Res Treat 65, 55–61 (2001). https://doi.org/10.1023/A:1006458601568

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006458601568

Search

Navigation